Keros Therapeutics (NASDAQ:KROS) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Keros Therapeutics to “strong buy” from “hold.” Analysts’ overall consensus is “Moderate Buy,” with an average price target of $21.40.
• Keros reported quarterly EPS of $0.70, beating the consensus estimate of a $0.96 loss, and revenue of $40.01 million versus analysts’ $14.76 million estimate.
• The company authorized a $5 million share-repurchase plan, allowing it to buy back up to 2.3% of its outstanding shares.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Monday, Zacks reports.

Other research analysts also recently issued reports about the company. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wells Fargo & Company decreased their price target on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Tuesday, August 4th. Leerink Partners decreased their price target on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research note on Tuesday, August 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a report on Tuesday. Finally, Wall Street Zen upgraded Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.40.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $9.33 on Monday. Keros Therapeutics has a 52 week low of $8.98 and a 52 week high of $22.55. The firm has a 50 day moving average of $11.11 and a 200 day moving average of $11.82.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $1.66. The business had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.85%. Equities research analysts anticipate that Keros Therapeutics will post -4.45 EPS for the current year.

Keros Therapeutics declared that its board has authorized a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $5 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.

Insider Activity at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider directly owned 27,559 shares in the company, valued at $283,582.11. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 5,343 shares of company stock worth $54,985. 12.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Keros Therapeutics during the second quarter worth $29,898,000. Nantahala Capital Management LLC purchased a new position in shares of Keros Therapeutics in the second quarter worth about $15,091,483. Dimensional Fund Advisors LP lifted its stake in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company's stock worth $3,547,000 after buying an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics during the second quarter worth about $2,641,000. Finally, Man Group plc acquired a new position in Keros Therapeutics during the second quarter worth about $1,664,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

Trending Headlines about Keros Therapeutics

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its 2026 and 2027 earnings estimates. Separately, Zacks said KROS’s roughly 21% decline over four weeks had pushed it into oversold territory, which could leave room for a rebound if selling pressure eases. Zacks article
• Neutral Sentiment: A report listed short interest at zero shares and a zero-day short-interest ratio. The figure offers little indication of short-selling pressure, though it conflicts with the entry’s description of a large increase.
• Negative Sentiment: Keros is still forecast to report losses, and HC Wainwright trimmed its 2028–2030 earnings estimates. Those revisions point to ongoing uncertainty about the pace of the company’s path to profitability.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros' investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.